DeepMind:AI可將新藥發現時長由數年縮短至幾個月內 甚至更快
Alphabet(GOOG.US)人工智能實驗室DeepMind行政總裁、諾貝爾獎得主Demis Hassabis接受《彭博》專訪時表示,發現新藥需時數年,且伴隨着驚人的失敗率,但未來幾年內,他相信透過AI可將有關時長將縮短至幾個月,甚至更快。
Hassabis負責Google DeepMind的AI部門,以及專注於藥物發現的Alphabet子公司Isomorphic Labs。Isomorphic Labs自2021年成立以來,已與製藥公司禮來(LLY.US)和諾華製藥(NVS.US)達成合作協議。雖然目前尚未有AI設計的藥物成功完成臨牀試驗,但Hassabis曾於1月時透露其公司將於年底前開始AI設計藥物的臨牀試驗,並於9月初表示公司已展示出「幾個初步的證明論點」以推進藥物進入試驗,惟並未提供具體的時間更新。
他亦曾表示,Isomorphic Labs可能會建立一個價值超過1,000億美元的業務。該公司在今年初完成一輪由Thrive Capital主導的6億美元融資。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.